Cell Reports (Mar 2016)

Insertional Mutagenesis Identifies a STAT3/Arid1b/β-catenin Pathway Driving Neurofibroma Initiation

  • Jianqiang Wu,
  • Vincent W. Keng,
  • Deanna M. Patmore,
  • Jed J. Kendall,
  • Ami V. Patel,
  • Edwin Jousma,
  • Walter J. Jessen,
  • Kwangmin Choi,
  • Barbara R. Tschida,
  • Kevin A.T. Silverstein,
  • Danhua Fan,
  • Eric B. Schwartz,
  • James R. Fuchs,
  • Yuanshu Zou,
  • Mi-Ok Kim,
  • Eva Dombi,
  • David E. Levy,
  • Gang Huang,
  • Jose A. Cancelas,
  • Anat O. Stemmer-Rachamimov,
  • Robert J. Spinner,
  • David A. Largaespada,
  • Nancy Ratner

DOI
https://doi.org/10.1016/j.celrep.2016.01.074
Journal volume & issue
Vol. 14, no. 8
pp. 1979 – 1990

Abstract

Read online

To identify genes and signaling pathways that initiate Neurofibromatosis type 1 (NF1) neurofibromas, we used unbiased insertional mutagenesis screening, mouse models, and molecular analyses. We mapped an Nf1-Stat3-Arid1b/β-catenin pathway that becomes active in the context of Nf1 loss. Genetic deletion of Stat3 in Schwann cell progenitors (SCPs) and Schwann cells (SCs) prevents neurofibroma formation, decreasing SCP self-renewal and β-catenin activity. β-catenin expression rescues effects of Stat3 loss in SCPs. Importantly, P-STAT3 and β-catenin expression correlate in human neurofibromas. Mechanistically, P-Stat3 represses Gsk3β and the SWI/SNF gene Arid1b to increase β-catenin. Knockdown of Arid1b or Gsk3β in Stat3fl/fl;Nf1fl/fl;DhhCre SCPs rescues neurofibroma formation after in vivo transplantation. Stat3 represses Arid1b through histone modification in a Brg1-dependent manner, indicating that epigenetic modification plays a role in early tumorigenesis. Our data map a neural tumorigenesis pathway and support testing JAK/STAT and Wnt/β-catenin pathway inhibitors in neurofibroma therapeutic trials.